Your search for apixaban returned 12 results

While the use of NSAIDs was low in the ARISTOTLE trial, NSAID users had a higher risk for bleeding than non-users.

ANNEXA-4 is a global, single-arm, open-label clinical trial designed to evaluate andexanet alfa in patients who present with an acute major bleed while receiving apixaban, rivaroxaban, edoxaban or enoxaparin.

Apixaban is a substrate of P-glycoprotein and P-glycoprotein inhibition increases drug exposure.

End-stage renal disease patients on dialysis with atrial fibrillation are at high risk for thrombotic complications.

This is an investigational use for Eliquis.

The 28-year-old male patient presented with acute-onset vertigo, nausea, vomiting, and unsteady gait.

The researchers searched the U.S. Medicare database for NVAF patients 65 years of age and older who were newly prescribed one of the following medications: apixaban, dabigatran, rivaroxaban, or warfarin.

Neurologists, internists and cardiologists differ markedly in their prescribing beliefs when it comes to the prevention of ischemic stroke due to atrial fibrillation, according to survey results.

Older patients, females, and those with comorbidities were more likely to be on multiple medications.

Researchers conducted a post hoc analysis of the ARISTOTLE trial which included patients with atrial fibrillation (AF) and a risk of stroke treated with either apixaban or warfarin for the prevention of stroke/ systemic embolism.